Clasado agrees US prebiotic distribution deal with Stauber

Stauber has acquired non-exclusive rights to distribute Clasado’s Bimuno prebiotic ingredient

Clasado Biosciences, a gut health-focused company, has granted Stauber non-exclusive rights to distribute its Bimuno prebiotic ingredient. Bimuno uses a unique proprietary galactooligosaccharides (GOS) mixture to feed and stimulate the growth of bifidobacteria, a type of 'good bacteria'; in the gut.

Putting today's consumer need for digestive health firmly at the forefront, the ingredient is the result of an ongoing research and development programme conducted with globally recognised research institutes including the University of Reading and King's College London.

Bimuno is supported by over 80 scientific publications, making a very widely studied prebiotic. Under the agreement, Stauber, a US supplier to the nutritional, pharmaceutical, cosmetic and pet care industries, will be a non-exclusive distributor for Bimuno, boasting a significant infrastructure of strategically located distribution centres across North America, further boosting the geographic reach of Bimuno.

Per Rehné, CEO at Clasado Biosciences, said: "We share the belief that science-backed digestive health should be effective and accessible to everyone. Gut health is particularly important as we know that >70% of immune cells are located in the gut. Consumers are seeking new ways to bolster and support the wider functions of the body and Bimuno is a demonstrable way to do this."

"Bimuno is a nutritional technology meeting a clear consumer need, providing a simple and intuitive approach to gut health that meets the demand for convenience. The North American market is one of the fastest growing geographies for prebiotic supplements and we're excited about the opportunity that lies ahead for Clasado to grow in this region," Rehné added.

The comprehensive science behind Bimuno has delivered a strong portfolio of benefits to the second-generation prebiotic. Alongside its core function of stimulating the growth of bifidobacteria, additional studies also indicate improvements in gastrointestinal discomfort, immune system modulation and anti-pathogenic activity. Through the gut-brain axis, research also suggests heightened cognition and improved sleep health.

Companies